Astellas Pharma Europe Ltd.: Observational study in Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer (1000 participants)
Astellas Pharma Europe Ltd.: Observational study in Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer (1000 participants). Its enrollment of 1,000 is top-decile (94th percentile of 8,879 records). Dated 31 days ago, it serves as a historical benchmark. Score 60/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 1,000 · 94th percentile of 8,879 ClinicalTrialStartPulse records · 12.5x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Astellas Pharma Europe Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE) |
| NCT ID | NCT07858500 |
| Phase | Observational |
| Status | not yet recruiting |
| Conditions | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma |
| Intervention types | drug |
| Target enrollment | 1000 |
| Site countries | Canada |
| Posted | 2026-10-05 |
| Planned start | 2027-01-31 |
| Event | Newly registered study |
| Event date | 2026-10-05 |
| enrollment percentile | 94th of 8,879 (median 80, 12.5x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Astellas Pharma Europe Ltd.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Astellas Pharma Europe + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-05
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Astellas Pharma Europe Ltd. and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Astellas Pharma Europe Ltd.'s enrollment: 94th percentile of 8,879 records
- Timing: Low: older than 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
60 / 100 Score
- Industry sponsor (buys outsourced services).
- 1000 participants planned.
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for Astellas Pharma Europe Ltd.?
Astellas Pharma Europe Ltd. registered a Observational study (NCT07858500) in Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer targeting 1000 participants, posted 2026-10-05.
How does Astellas Pharma Europe Ltd. compare to other ClinicalTrialStartPulse records?
This is a top-decile record: its enrollment of 1,000 is 12.5x the median of 80 across 8,879 records. It is 31 days old, still within a typical 45-day follow-up window.
Astellas Pharma Europe Ltd. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Astellas Pharma Europe Ltd. | NONUS | 1,000 | 94th | 2026-10-05 |
| Janssen Pharmaceutica N.V., Belgium | NONUS | 1,314 | 95th | 2026-11-03 |
| Hoffmann-La Roche | NONUS | 1,800 | 96th | 2026-10-30 |
| Janssen-Cilag International NV | NONUS | 135 | 68th | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Observational ClinicalTrialStartPulse: Outside the US only ClinicalTrialStartPulse: 1,000+
How to monitor Astellas Pharma Europe Ltd. and peer observational records
Get new ClinicalTrialStartPulse records like Astellas Pharma Europe Ltd. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.